"Interleukin-2" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A soluble substance elaborated by antigen- or mitogen-stimulated T-LYMPHOCYTES which induces DNA synthesis in naive lymphocytes.
| Descriptor ID |
D007376
|
| MeSH Number(s) |
D12.644.276.374.465.021 D12.644.276.374.480.372 D12.776.467.374.465.021 D12.776.467.374.480.372 D23.529.374.465.155 D23.529.374.480.372
|
| Concept/Terms |
Interleukin-2- Interleukin-2
- Interleukin 2
- IL-2
- IL2
- TCGF
- Interleukine 2
- Lymphocyte Mitogenic Factor
- Mitogenic Factor, Lymphocyte
- T-Cell Growth Factor
- T Cell Growth Factor
- T-Cell Stimulating Factor
- T Cell Stimulating Factor
- Thymocyte Stimulating Factor
- Interleukin II
Ro-23-6019- Ro-23-6019
- Ro 23 6019
- Ro236019
- Ro-236019
- Ro 236019
|
Below are MeSH descriptors whose meaning is more general than "Interleukin-2".
Below are MeSH descriptors whose meaning is more specific than "Interleukin-2".
This graph shows the total number of publications written about "Interleukin-2" by people in this website by year, and whether "Interleukin-2" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1996 | 3 | 2 | 5 |
| 1997 | 1 | 0 | 1 |
| 1998 | 2 | 4 | 6 |
| 1999 | 0 | 1 | 1 |
| 2000 | 1 | 0 | 1 |
| 2001 | 0 | 3 | 3 |
| 2003 | 2 | 3 | 5 |
| 2004 | 2 | 1 | 3 |
| 2005 | 1 | 3 | 4 |
| 2006 | 3 | 4 | 7 |
| 2007 | 3 | 1 | 4 |
| 2008 | 1 | 2 | 3 |
| 2009 | 2 | 1 | 3 |
| 2010 | 2 | 2 | 4 |
| 2011 | 2 | 5 | 7 |
| 2012 | 3 | 1 | 4 |
| 2014 | 1 | 1 | 2 |
| 2015 | 1 | 2 | 3 |
| 2017 | 1 | 0 | 1 |
| 2018 | 3 | 0 | 3 |
| 2019 | 0 | 1 | 1 |
| 2020 | 1 | 0 | 1 |
| 2021 | 0 | 1 | 1 |
| 2022 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Interleukin-2" by people in Profiles.
-
Molecular and pro-inflammatory aspects of COVID-19: The impact on cardiometabolic health. Biochim Biophys Acta Mol Basis Dis. 2022 12 01; 1868(12):166559.
-
CD4 Inhibits Helper T Cell Activation at Lower Affinity Threshold for Full-Length T Cell Receptors Than Single Chain Signaling Constructs. Front Immunol. 2020; 11:561889.
-
ALKS 4230: a novel engineered IL-2 fusion protein with an improved cellular selectivity profile for cancer immunotherapy. J Immunother Cancer. 2020 04; 8(1).
-
The lineage stability and suppressive program of regulatory T cells require protein O-GlcNAcylation. Nat Commun. 2019 01 21; 10(1):354.
-
Pilot trial of the hu14.18-IL2 immunocytokine in patients with completely resectable recurrent stage III or stage IV melanoma. Cancer Immunol Immunother. 2018 Oct; 67(10):1647-1658.
-
Enhanced Lymphodepletion Is Insufficient to Replace Exogenous IL2 or IL15 Therapy in Augmenting the Efficacy of Adoptively Transferred Effector CD8+ T Cells. Cancer Res. 2018 06 01; 78(11):3067-3074.
-
IL-2 and Beyond in Cancer Immunotherapy. J Interferon Cytokine Res. 2018 02; 38(2):45-68.
-
Murine Th17 cells utilize IL-2 receptor gamma chain cytokines but are resistant to cytokine withdrawal-induced apoptosis. Cancer Immunol Immunother. 2017 Jun; 66(6):737-751.
-
Human intrahepatic regulatory T cells are functional, require IL-2 from effector cells for survival, and are susceptible to Fas ligand-mediated apoptosis. Hepatology. 2016 07; 64(1):138-50.
-
Costimulation Endows Immunotherapeutic CD8 T Cells with IL-36 Responsiveness during Aerobic Glycolysis. J Immunol. 2016 Jan 01; 196(1):124-34.